Imaging Biomarkers for Alzheimer’s Care

As amyloid‑targeting therapies advance, imaging biomarkers are becoming essential for efficient and informed patient management in Alzheimer’s disease.

With the approval of Lecanemab and Donanemab, new therapeutic possibilities have emerged — but so have new challenges. Clinicians must now navigate high treatment costs, mixed therapeutic effectiveness, and significant risks, all while ensuring that each patient receives the most appropriate care.

This is exactly where imaging can provide crucial guidance.

Our ASL‑MRI biomarkers may show meaningful correlations with later cognitive outcomes. They can help patients and neurologists gain additional insights when considering whether a therapy should be continued, adjusted, or stopped. In a treatment landscape where responses vary widely, such biomarkers may offer valuable support for more personalized and responsible care. More insight on the topic can be found in the recording of our webinar ” Why do so many Alzheimer’s trials fail to deliver actionable insights ” which we hosted together with wemedo: LINK